MA26923A1 - Derives de sulfonyl-pyrrolidine utiles pour le traitement des desordres neurologiques - Google Patents

Derives de sulfonyl-pyrrolidine utiles pour le traitement des desordres neurologiques

Info

Publication number
MA26923A1
MA26923A1 MA26983A MA26983A MA26923A1 MA 26923 A1 MA26923 A1 MA 26923A1 MA 26983 A MA26983 A MA 26983A MA 26983 A MA26983 A MA 26983A MA 26923 A1 MA26923 A1 MA 26923A1
Authority
MA
Morocco
Prior art keywords
sulfonyl
treatment
neurological disorders
derivatives useful
pyrrolidine derivatives
Prior art date
Application number
MA26983A
Other languages
English (en)
Inventor
Vincent Mutel
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26923A1 publication Critical patent/MA26923A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Oncology (AREA)
MA26983A 2000-06-30 2002-12-27 Derives de sulfonyl-pyrrolidine utiles pour le traitement des desordres neurologiques MA26923A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00113894 2000-06-30

Publications (1)

Publication Number Publication Date
MA26923A1 true MA26923A1 (fr) 2004-12-20

Family

ID=8169121

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26983A MA26923A1 (fr) 2000-06-30 2002-12-27 Derives de sulfonyl-pyrrolidine utiles pour le traitement des desordres neurologiques

Country Status (34)

Country Link
US (2) US6589978B2 (fr)
EP (1) EP1299383B1 (fr)
JP (1) JP3994051B2 (fr)
KR (1) KR100529423B1 (fr)
CN (1) CN1178936C (fr)
AR (1) AR029288A1 (fr)
AT (1) ATE286895T1 (fr)
AU (2) AU8187701A (fr)
BR (1) BR0112093A (fr)
CA (1) CA2413243A1 (fr)
CZ (1) CZ2003280A3 (fr)
DE (1) DE60108394T2 (fr)
DK (1) DK1299383T3 (fr)
EC (1) ECSP024403A (fr)
ES (1) ES2234869T3 (fr)
HR (1) HRP20021023B1 (fr)
HU (1) HUP0301167A3 (fr)
IL (2) IL153425A0 (fr)
JO (1) JO2384B1 (fr)
MA (1) MA26923A1 (fr)
MX (1) MXPA02012270A (fr)
MY (1) MY126903A (fr)
NO (1) NO324218B1 (fr)
NZ (1) NZ523025A (fr)
PE (1) PE20020103A1 (fr)
PL (1) PL360396A1 (fr)
PT (1) PT1299383E (fr)
RU (1) RU2272026C2 (fr)
SI (1) SI1299383T1 (fr)
TW (1) TWI265928B (fr)
UY (1) UY26812A1 (fr)
WO (1) WO2002002554A1 (fr)
YU (1) YU99702A (fr)
ZA (1) ZA200209966B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256186B2 (en) 2002-02-06 2007-08-14 Schering Corporation Gamma secretase inhibitors
US20040171614A1 (en) * 2002-02-06 2004-09-02 Schering-Plough Corporation Novel gamma secretase inhibitors
TW200302717A (en) 2002-02-06 2003-08-16 Schering Corp Novel gamma secretase inhibitors
DE10240818A1 (de) * 2002-08-30 2004-05-13 Grünenthal GmbH Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate
GB0225938D0 (en) * 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
KR20070010144A (ko) * 2004-04-05 2007-01-22 쉐링 코포레이션 신규한 감마 세크레타제 억제제
EP1758884A2 (fr) * 2004-05-20 2007-03-07 Elan Pharmaceuticals, Inc. Inhibiteurs sulfonamido n-cycliques de gamma-secretase
CN101602741A (zh) 2004-06-30 2009-12-16 先灵公司 作为γ-分泌酶抑制剂的取代的N-芳基磺酰基杂环胺
ATE491693T1 (de) * 2004-07-22 2011-01-15 Schering Corp Substituierte amide als inhibitoren der beta- sekretase
EP2336107B1 (fr) 2004-09-30 2015-09-23 Takeda Pharmaceutical Company Limited Inhibiteurs de pompe a protons
ZA200708445B (en) * 2005-04-04 2009-03-25 Takeda Pharmaceutical Preventive or remedy for depression or anxiety neurosis
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
EP2327692B9 (fr) 2005-08-30 2014-06-04 Takeda Pharmaceutical Company Limited Dérivés de1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl-1-H-pyrrole substitués et leur utilisation en tant qu'inhibiteurs de la sécrétion d'acide gastrique
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenèse induite par le récepteur 5ht
WO2007134136A2 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenèse par modulation de l'angiotensine
EP2068872A1 (fr) 2006-09-08 2009-06-17 Braincells, Inc. Combinaisons contenant un dérivé de 4-acylaminopyridine
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
MX2009003382A (es) * 2006-09-29 2009-04-08 Gruenenthal Gmbh Derivados de sulfonamidas sustituidos.
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
HUE031580T2 (en) * 2008-08-15 2017-07-28 Nivalis Therapeutics Inc Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
PE20110300A1 (es) 2008-08-27 2011-06-16 Takeda Pharmaceutical Compuestos de pirrol como inhibidores de la bomba de protones
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
ES2351323B1 (es) * 2009-06-26 2011-10-05 Institut Univ. De Ciència I Tecnologia, S.A. Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para el descubrimiento de farmacos.
ES2351452B1 (es) * 2009-07-01 2011-10-05 Institut Univ. De Ciència I Tecnologia, S.A. Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para la identificacion de actividad biologica y farmacologica.
US20240327392A1 (en) * 2021-06-25 2024-10-03 Albius Sciences Alpha Private Limited Heterocycloalkyl-substituted polyheteroazole derivatives as medicaments for treating and/or preventing rs virus infections

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3905979A (en) * 1974-05-09 1975-09-16 Stanford Research Inst Diazabicyclooctanes and diazabicycloheptanes
US4539411A (en) * 1982-02-05 1985-09-03 Hoffmann-La Roche Inc. Rhodium complexes of chiral phosphines
US5036153A (en) * 1989-05-11 1991-07-30 Braish Tamim F Preparation of 2,5-diazabicyclo[2.2.1]heptanes and intermediates
US6417198B1 (en) * 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
GB9612884D0 (en) 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
US5721256A (en) 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
US6271252B1 (en) 1997-11-24 2001-08-07 Merck & Co., Inc. Cyclic amino acid derivatives as cell adhesion inhibitors
US6645939B1 (en) * 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
GB9804426D0 (en) 1998-03-02 1998-04-29 Pfizer Ltd Heterocycles
AT411339B (de) 1998-05-13 2003-12-29 Fronius Schweissmasch Prod Verfahren zum steuern eines schweissgerätes und steuervorrichtung hierfür
CN1306525A (zh) 1998-06-03 2001-08-01 Gpinil控股公司 含有多个杂原子的杂环化合物的羧酸或其电子等排物
ATE293622T1 (de) 1998-12-18 2005-05-15 Schering Corp Farnesyl protein transferase inhibitoren
HUP0201295A3 (en) * 1999-01-27 2002-10-28 Ortho Mcneil Pharm Inc Peptidyl heterocyclic ketones useful as tryptase inhibitors
TW575561B (en) 1999-03-25 2004-02-11 Hoffmann La Roche 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives
ES2296618T3 (es) * 1999-05-20 2008-05-01 Dong Wha Pharmaceutical Industrial Co. Ltd. Derivados opticamente activos de acidos quinolin-carboxilicos que tienen sustituyentes de 7-pirrolidina que provocan actividad optica y un procedimiento para la preparacion de estos.
US6143776A (en) * 2000-02-02 2000-11-07 Sunesis Pharmaceuticals, Inc. Tosylproline analogs as thymidylate synthase inhibitors

Also Published As

Publication number Publication date
ATE286895T1 (de) 2005-01-15
US6589978B2 (en) 2003-07-08
HK1058358A1 (en) 2004-05-14
AR029288A1 (es) 2003-06-18
DE60108394D1 (de) 2005-02-17
EP1299383A1 (fr) 2003-04-09
CZ2003280A3 (cs) 2003-12-17
YU99702A (sh) 2006-05-25
IL153425A0 (en) 2003-07-06
EP1299383B1 (fr) 2005-01-12
US6995182B2 (en) 2006-02-07
JP2004502688A (ja) 2004-01-29
CN1178936C (zh) 2004-12-08
MY126903A (en) 2006-10-31
DK1299383T3 (da) 2005-05-23
AU8187701A (en) 2002-01-14
NO324218B1 (no) 2007-09-10
US20030212066A1 (en) 2003-11-13
JP3994051B2 (ja) 2007-10-17
TWI265928B (en) 2006-11-11
US20020019424A1 (en) 2002-02-14
UY26812A1 (es) 2001-12-28
DE60108394T2 (de) 2006-03-02
KR20030011378A (ko) 2003-02-07
NO20026263D0 (no) 2002-12-27
PT1299383E (pt) 2005-05-31
IL153425A (en) 2007-08-19
ECSP024403A (es) 2003-02-06
RU2272026C2 (ru) 2006-03-20
PL360396A1 (en) 2004-09-06
PE20020103A1 (es) 2002-02-13
NZ523025A (en) 2004-04-30
CA2413243A1 (fr) 2002-01-10
SI1299383T1 (en) 2005-06-30
WO2002002554A1 (fr) 2002-01-10
KR100529423B1 (ko) 2005-11-17
ZA200209966B (en) 2004-03-09
BR0112093A (pt) 2003-05-13
HRP20021023A2 (en) 2004-08-31
CN1440405A (zh) 2003-09-03
NO20026263L (no) 2002-12-27
HUP0301167A2 (hu) 2003-08-28
JO2384B1 (en) 2007-06-17
HRP20021023B1 (en) 2006-08-31
MXPA02012270A (es) 2003-04-25
HUP0301167A3 (en) 2009-12-28
ES2234869T3 (es) 2005-07-01
AU2001281877B2 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
NO20026263D0 (no) Sulfonyl-pyrrolidin-derivater anvendelige for behandling av neurologiske forstyrrelser
UA87653C2 (en) 1,2,4-oxadiazols as modulators of receptor-5 for metabotropic glutamate
JO2285B1 (en) Dihydro-benzoic derivatives
TNSN98203A1 (fr) Derives de thienopyrimidine et tienopyridine utiles comme agents anticancereux, et compositions les contenant
MY130369A (en) DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS mGLUR2 ANTAGONISTS II
BG105588A (en) Anthranilic acide amides and the use thereof as medicaments
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
MY176608A (en) Dihydrobenzodiazepin-2-one derivatives iii
ATE337780T1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
MY126917A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
NZ526868A (en) Substituted alkylamine derivatives and methods of use for treating cancer and angiogenesis related disorders
TNSN01124A1 (fr) Derives de 1,4-dihydropyridine nouveaux , servant d'antagonistes de la bradykinine, et compositions les contenant
EP1638950A4 (fr) Derives de cyclohexylglycine servant d'inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
MA27647A1 (fr) Antagonistes de ccr5 utiles comme agents therapeutiques
MY138394A (en) Combination of mglur2 antagonist and ache inhibitor
TNSN97044A1 (fr) Derives de quinoxalinedone, procedes et intermediaires pour leur preparation, et compositions pharmaceutiques les contenant.
TNSN99255A1 (fr) Derives de piperidine et de morpholine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
BR0008292A (pt) Derivados de mevinolina
MX9708416A (es) Derivados de piperazino como antagonistas de neuroquininas.
MXPA02011921A (es) Inhibidores de dipeptidasa acida n-acetilada-alfa-enlazada para el tratamiento de trastornos retinianos y glaucona.
BR9812531A (pt) Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica
BG101929A (en) Benzamides for neurodegenerative disorder treatment
MA26474A1 (fr) Derives de quinoxalinedione, procede pour leur preparation et compositions pharmaceutiques les contenant .
DE69722816D1 (de) Neue derivate von benzoylalkyl-1,2,3,6-tetrahydropyridinen
BG106488A (bg) Калциев комплекс на фосфор съдържащи етилендиаминови производни